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PERSPECTIVE FOR THE N DOMAIN SUBTITLE; MINIMALLY IN-
VASIVE MEDIASTINAL STAGING OF LUNG CANCER AND TISSUE 
ACQUISITION BY EBUS-TBNA
Bin Hwangbo  
Department Of Pulmonology, National Cancer Center, Gyeonggi/KOREA
Mediastinoscopy is the gold standard for preoperative mediastinal staging of lung 
cancer. Minimally invasive methods that can be alternatives to mediastinoscopy are 
conventional transbronchial needle aspiration (TBNA), endobronchial ultrasound 
guided-TBNA (EBUS-TBNA) and endoscopic ultrasound guided fine needle aspiration 
(EUS-FNA). Mediastinoscopy can access lymph nodes at stations 1, 2, 4, and 
subcarinal nodes. But, posterior parts of subcarinal nodes are difficult to be sampled by 
mediastinoscopy. Conventional TBNA is a blind procedure without real-time ultrasound 
guidance. It can access relatively large lymph nodes guided by endobronchial landmarks. 
EBUS-TBNA improved accessibility to mediastinal nodes. EBUS-TBNA can reach to 
all the mediastinal nodal stations accessible by mediastinoscopy. Retrotracheal nodes 
(3P) are also reachable and posterior parts of subcarinal nodes are easily accessed by 
EBUS-TBNA. N1 nodes (10R, 10L, 11Rs, 11Ri, 11L and some 12R&L nodes at lower 
lobes) can be sampled by EBUS-TBNA. High diagnostic values of EBUS-TBNA in 
mediastinal staging have been reported. According to meta-analyses, pooled sensitivities 
of EBUS-TBNA were 88-93%. Whether EBUS-TBNA can replace mediastinoscopy is an 
important issue in lung cancer staging. EBUS-TBNA is a less invasive procedure that can 
be performed under local anesthesia. Morbidity and complication rates of EBUS-TBNA 
are lower than mediastinoscopy. According to a study which compared EBUS-TBNA 
with mediastinoscopy in the staging of operable lung cancer, EBUS-TBNA had similar 
diagnostic values to mediastinoscopy. Mediastinoscopy following EBUS-TBNA can 
detect small metastasis which was missed by EBUS-TBNA, but clinical importance 
seems minimal. EUS-FNA has a different accessibility to the mediastinum. EUS-FNA 
has limited ability to target pre-tracheal lesions that are easily accessed by EBUS-TBNA. 
However, EUS-FNA can access the inferior mediastinum (station 8 & 9) and some 
areas of the aorto-pulmonary window (station 5). Additional roles of trans-esophageal 
approach following EBUS-TBNA have been studied. By adding EUS-FNA with an 
EBUS bronchoscope following EBUS-TBNA, accessibility to mediastinal nodal stations 
increased by approximately 6%. Additional diagnostic gain was observed on lesions 
inaccessible or difficult to access by EBUS-TBNA. EUS-FNA following EBUS-TBNA on 
lesions inaccessible by EBUS-TBNA may be a reasonable approach in the mediastinal 
staging of operable lung cancer. EBUS-TBNA is used for lung cancer diagnosis and tissue 
acquisition as well as lung cancer staging. EBUS-TBNA on metastatic nodes or primary 
tumors provides samples for tissue diagnosis. In patients with emphysema or poor 
pulmonary function, lymph node sampling can be a safer method than transthoracic 
needle aspiration on primary tumors. Lymph node samples obtained by EBUS-TBNA 
can be used for molecular analysis such as EGFR and ALK mutation analysis. In 
conclusion, EBUS-TBNA has high diagnostic values in lung cancer staging. Sampling 
by EBUS-TBNA can provide good samples for lung cancer diagnosis and molecular 
analysis.
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NETHERLANDS
The National Lung Screening Trial (NLST) showed a statistically significant 20.3% 
reduction in lung cancer mortality using low dose CT (LDCT) scan as a non-invasive 
screening tool for all former and current heavy smokers - thus relatively healthy 
individuals - aged 55-74 with a >30 py smoking history.1 The Dutch National Health 
Care System reported recently that health care access remains excellent, but that rising 
health care costs due to the ageing population continue to increase at an alarming rate. 
However, robust data for comparison of quality of service and patient outcomes are 
still lacking.2 Enormous efforts in the last decades to improve lung cancer outcome 
have shown meager results with very sobering survival rate improvement.3 The ageing 
society may also suffer from co-morbidities requiring much more attention from all 
health care service providers.4 We need therefore to seriously put more attention to 
the cost-effectiveness of major early intervention programs in general, rather than 
focusing on obtaining stage shift as the best option for improving lung cancer survival 
rate only.5 Implicitly, we are equally responsible for enforcing affordable and accessible 
health care provisions in a civilized society for all, as the Netherlands is a full member 
state of the European Union. In the three rounds of LDCT screening of the NLST 
trial, the percentage of false positive test ranged from 95% to 98%: “Almost everyone 
who had a positive test result had a false positive…..”(1). Implementation in the Dutch 
society of the NLST- LDCT screening strategy using the same inclusion criteria will 
result in 1 less lung cancer death at the cost of € ~ 247,000 per person diagnosed,5 or 
roughly a total of € 438 million for only performing LDCT screening program. This, 
in order to prevent <1,600 lung cancer deaths in the relatively healthy smoking cohort 
population. The downstream costs of false positives have not been fully accounted for, 
while our health care systems are already stretched to the limit in dealing with current 
ageing morbid population.2,5 Clearly, the extremely large cohort of healthy smokers and 
high false positive rate from any upfront diagnostic test, will generate major hurdles 
for implementing a cost-efficient early interventional program. Better definition of 
the cohort at risk, inclusion of highly accurate or specific diagnostic tests - instead of 
applying increasingly sensitive diagnostic tools being continuously repeated - in major 
interventional programs in combination with practical curative local treatment for 
targeting the tumor domain at its earlier stages are a more logical strategy to pursue.6,7 
Exploration of more cost-efficient minimally invasive technologies in combining early 
diagnosis, tumor localization and curative treatment using current advancements by 
real time image guided catheter optics is warranted. This strategy has already been 
implemented for the worst at risk category of patients in an outpatient setting by virtue 
of its lower morbidity.6-8 Together with less invasive method such as exhaled breath 
analysis and biomarkers,9-11 the use of real time image guided navigational catheter 
optics may fullfil our need for a one-stop-day-care interventional facility. This strategy 
also provides a research platform for in vivo and in situ clonal dynamic studies on 
carcinogenesis and early disease processes in general, rather than performing transversal 
population studies.12,13 However, validation requires still arduous and longitudinal 
studies due to the long lead time of carcinogenesis in the cohort at risk.11,13  
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COMPREHENSIVE DIAGNOSTIC AND THERAPEUTIC BRON-
CHOSCOPY FOR CENTRAL TYPE LUNG CANCER  
Norihiko Ikeda  
Surgery I, Tokyo Medical University, Tokyo/JAPAN
Due to advances in interventional bronchoscopy, curative treatment has become possible 
for central type lung cancer if it is detected in the early stage. However, the evaluation 
of the extent of tumor invasion and the depth of tumor involvement by conventional 
white light bronchoscopy alone is too subjective. The development of autofluorescence 
bronchoscopy (AFB) and endobronchial ultrasonography (EBUS) has had a large impact 
on diagnostic bronchoscopy in the past decade and have been employed especially 
for the sophisticated diagnosis as well as optimal selection of the therapeutic strategy 
for central type early lung cancer (CELC) (1). Tumor localization represents the most 
important step for the management of CELC. Conventional bronchoscopy is sometimes 
insufficient for the early detection of intraepithelial lesions, especially in case of the flat 
type tumor. Improved localization of such subtle lesions by AFB was recognized. AFB 
also is recommended for localization of the lesion especially for patients with abnormal 
sputum cytology findings (2). Endoscopic treatment would be a promising alternative 
for selected CELC patients with comorbidities, however lesions would have to be limited 
to within the cartilagenous layer of the bronchial wall to enable successful endoscopic 
treatment (3). If the tumor invades beyond the cartilaginous layer, photodynamic 
therapy (PDT) or other endobronchial therapeutical modalities should not be applied 
due to the limited light penetration, and surgery should be selected. The accurate 
evaluation of peribronchial tumor invasion as well as lymph node swelling is important 
prior to any endoscopic treatment. Endobronchial ultrasonography (EBUS) will enhance 
the determination the depth of tumor invasion. Bronchoscopic optical coherence 
tomography (OCT) will be widely applied in the near future(1). The early experience 
has revealed that endoscopic OCT examination provides high resolution images of 
the bronchial surface, making possible detailed examination of intraepithelial lesions 
(4),(5). We postulated that since new photosensitizer, NPe6 has a longer absorption 
band (664nm) than that of Photofrin (630nm), PDT using NPe6 would have greater 
photodynamic efficacy due to a slight gain in the penetration depth of light than that 
with Photofrin. NPe6 may have a similar treatment outcome regardless of tumor size, 
as long sufficient laser illumination of the entire tumor is possible (6),(7). The present 
guidelines of PDT for CELC were established based on the data in the previous era; 
bronchoscopists decided on the indications of PDT solely using white light bronchoscopy 
and performed PDT with Photofrin. We postulate that more comprehensive diagnostic 
techniques and new generation photosensitizers may increase the cure rate and expand 
the indications of PDT for larger tumors with less side effect (8). NPe6 was approved 
for the treatment of CELC by Japanese Ministry of Health, Labour and Welfare in 
2004 and also for advanced lung cancer in 2010. (1) Ikeda N, Hayashi A, Iwasaki K, et 
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CLINICAL CHARACTERISTICS IN ASIAN LUNG CANCER
Sumitra Thongprasert  
Department Of Medicine, Chiangmai University, Chiangmai/THAILAND
Clinical characteristic of Lung Cancer in ASIA differed from the west because 
of the difference in the risk factors, the difference in pharmacogenomics and 
pharmacodynamics. The major risk factors which are difference related to the 
high incidence of non-smoker related lung cancer in female. The difference in 
pharmacokinetics in drug metabolism and enzymes are clearly seen in several Asian 
study both by clinical observation and laboratory confirmation especially the study of 
Docetaxel. The comparable efficacy and toxicity of the common arm chemotherapy in 
the SWOG trial and the Japanese trial. The metabolism of several chemotherapeutics 
drug via CYP are also differed between Asia and the west. Polymorphisms within the 
CYP1A1gene have been shown to be associated with lung cancer risk, predominantly 
among Asian populations, an MspI cut site in an intron (CYP1A1 MspI) and an 
isoleucine to valine change in the heme binding region of the enzyme (CYP1A1 
Ile462Val) have generally been associated with moderate to high increased risk of lung 
cancer in Asian population. CYP1A1 I462V genotype (combined ile/val and val/val) was 
significantly associated with lung cancer risk in a Chinese population, the association 
was more pronounced among non-smokers than among smokers. The subjects carried 
CYP1A1*2C allele were found to be associated with high lung cancer risks in a north 
Indian population. However, neither CYP1A1 MspI nor CYP1A1Ile462Val was 
associated with lung cancer susceptibility among Caucasians or African-Americans. 
Among Caucasians, CYP1B1 Leu432Val appeared to be associated with the highest risk 
of lung cancer. The subjects homozygous for the cytochrome P450 2A6 (CYP2A6) *4 
have a lower risk of lung cancer and the male smokers possessing the CYP 2A6 *1A/*1A 
genotype have higher risk for tobacco-induced lung cancers. The higher incidence of 
EGFR mutation in Asia compared to the US and Europe is well established and lead to 
the better results of the treatment outcome. 
Keyword: Asia Lung Cancer, clinical, Pharmacogenomic
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GENDER DIFFERENCE IN LUNG CANCER
Alex Y. Chang  
Medical Oncology, Johns Hopkins Singapore Int’L Medical Center, Singapore/
SINGAPORE
Many gender differences in lung cancer have been recognized while controversies 
surrounding the issue do exist. Lung cancer is the leading cause of cancer mortality in 
the world with tobacco use as the major cause of lung cancer. 80% of male or female 
Caucasian patients smoke as compared to only 10% or less of Asian female lung cancer 
patients smoke in Asia. This suggests that different etiologies or risk factors such as 
environmental exposure, hormone factors, genetic disposition may play a role in lung 
carcinogenesis in Asian and non-smoking Caucasian women. It was initially reported 
that females might be more susceptible to cigarette smoking and required less exposure 
to develop lung cancer. This is a theory has been recently challenged. In addition, 
multiple clinical observations have indicated that female patients tend to have more 
adenocarcinoma, a higher EGFR mutation, better response to chemotherapy and a 
longer survival than their male counterparts. It is therefore important and imperative 
to understand the biological basis for these clinical differences so that personalised 
treatment could be implemented for better preventive and therapeutic results.
Keywords: Gender Differences, LUNG CANCER
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DIAGNOSIS OF MALIGNANT MESOTHELIOMA
Takashi Nakano  
Department Of Internal Medicine, Hyogo College Of Medicine, Hyogo/JAPAN
Introduction: Malignant mesothelioma, of which incidence is increasing in almost all 
industrialized countries but declining in US, is characterized by its association with 
commercially used asbestos fibers such as crocidolite, amosite and chrysotile, and its 
long latency period of 40 years. High iron content of amphiboles fibers contribute to 
their higher carcinogenic potential. The highest carcinogenic fiber crocidolite contains 
as much as 36% iron by weight. The serpentine fiber chrysotile contains no iron in 
chemical composition, and is considered less carcinogec than amphibole fiber. Recently, 
chrysotile-induced mesothelial carcinogenesis has been found to be closely associated 
with iron overload in experimental models. Asbestos fibers generate reactive oxygen 
species and nitrogen species and cause oxidant stimulation. Paradoxically, antioxidant 
enzymes such as manganese superoxide dismutase are up-regulated. Thioredoxin is 
a 12 kD-oxidoreductase enzyme, and acts as one of antioxidants. Overexpression of 
thioredoxin and thiredoxin reductase has been demonstrated in mesothelioma cells. 
Clinically, the level of thioredoxin-1 in serum is significantly increased in patients 
with malignant pleural mesothelioma(MPM). In screening programs for high-risk 
population with asbestos exposure, previous radiological studies have proved ineffective 
for the detection of early stage mesothelioma. Reliable screening biomarker of early 
mesothelioma or even of pre-clinical asbestos-related tumors has not been established. 
Recently, some data suggest that erionite is associated with mesothelioma, and BAP1 
mutation may play a significant role in MPM. 
 
Diagnostic Approach 
Patients with early MPM frequently present with asymptomatic pleural effusion as 
the first clinical sign, therefore fluid cytology is the first step for diagnosis. But it is 
not recommended to make a diagnosis of MPM based on cytology alone because of 
high-risk diagnostic error. The malignant cells can be indistinguishable from benign, 
reactive mesothelial cells or even macrophages. Frequently, cytologic samples, even when 
patients already have mesothelioma, show negative or only subtle abnormalities. ERS/
ESTS (Eur Respir J, 2010) and IMIG Guidelines(Arch Pathol Lab Med, 2009) recommend 
that a cytological suspicion of mesothelioma is followed by tissue confirmation. Some 
biomarkers, i.e., SMRP, VEGF, increase with disease status. CEA level is usually low 
in mesothelioma. Blind fine needle biopsy of the pleura is usually not diagnostic for 
early stage MPM because of small inadequate samples and the same problems in fluid 
cytology. Thoracoscopy, either medical or VATS, is the key method to obtain sufficient 
materials for diagnostic investigation, allowing immunohistochemical characterization 
and adequate visual examination in the pleural cavity for clinical evaluation of T1-2 
status. Morphologically, mesotheliomas are classified as epithelioid, sarcomatoid, 
biphasic, and less commonly as desmoplastic subtype. Epithelioid subtype is the 
most common form of MPM, and has better outcomes of therapy. It is important that 
pathologist not only establishes the diagnosis but defines a morphological subtype 
for mesothelioma. Nonepithelioid histology is one of poor prognostic factors in MPM 
and consistently associated with poor survival. The panel of NCCN Guidelines(2012) 
does not recommend surgery for patients with sarcomatoid subtype. Other important 
poor prognostic factors are poor performance status, male gender, low Hb, high WBC, 
and high LDH. Increments of serum biomarker levels, SMRP, VEGF, angiopoietin-1 
and thioredoxin-1, are also poor prognosis predictor. Immunohistochemistry plays 
an important role in the diagnosis of mesothelioma. Positive mesothelioma markers, 
which are positive in mesothelioma and negative in adenocarcinoma, are Calretinin, 
Cytokeratin 5/6, WT-1, and D2-40. And, negative 　mesothelioma markers, negative in 
mesothelioma and positive in adenocarcinoma, are CEA, Ber-EP4, TTF-1, MOC-31 and 
Leu-M1. A diagnosis of mesothelioma should be always based on immunohistochemical 
examination (ERS/ESTS-Guidelines Grade 1A), but biphasic subtype is easy one to 
identify pathologically, prior to the routine use of immunohistochemistry. The most 
usual pathological diagnostic problem is the differentiation of mesothelioma from 
benign reactive mesothelial proliferations, and sometimes from adenocarcinoma. 
The separation of benign and malignant proliferative lesions of the pleura, a clinically 
crucial distinction, continues to be an important area in which there is a high degree of 
discrepancy among experts. Stromal invasion is acknowledged as the single most reliable 
marker of malignancy in this situation, therefore, multiple, large and deep biopsies, 
including fat and/or muscle, should be obtained with thoracoscopy. There are many 
diagnostic modalities to identify patients with MPM. FDG/PET is an accurate modality 
to diagnose and to estimate the extent of locoregional and distant MPM recurrence, and 
it carries independent prognostic value. 
 
Clinical Presentation 
Some asymptomatic patients with pleural effusion demonstrate malignant mesothelioma 
cells in the fluids, however, no tumors of the pleura but pleural plaques are seen with 
thoracoscopy, whose biopsied materials show stromal invasion of malignant cells. There 
is no doubt that so-called “in-situ mesothelioma” exists. We have no consensus on 
pathological and clinical definition of in-situ mesothelioma Initially, some small tumors 
are limited to the parietal pleura with no involvement of visceral pleural surface(T1a), 
then tumors involves visceral pleura(T1b). T1 stage tumors are usually associated with 
a free pleural space and a large pleural effusion. Thoracoscopy with NBI and AFI system 
is a useful diagnostic examination for T1a stage. With tumor growth, CT scan shows a 
typical finding of confluent growth of the pleural tumor including interlobar fissure(T2). 
And, tumor usually extends to the underlying lung parenchyma and diaphragmatic 
muscle. Surgical treatment with pleurectomy/decortications (P/D) cannot rid the patient 
of all macroscopic tumors at this clinical stage, but extrapleural pneumonectomy can 
do it. When tumor invades diaphragmatic muscle more and extends into the abdominal 
cavity, ascites develops(transdiaphragmatic spread). MR imaging can define involvement 
of the diaphragm. The most typical finding is that mesothelioma cells frequently seed at 
a site of needle tracts and chest tube drainage because of PDGF-D/PDGF-ββ mediated 
chemotaxis. 
 
Conclusion 
Malignant mesothelioma is a highly lethal and particular refractory tumor for which 
multimodal treatments have been far from satisfactory in achieving survival benefit. 
At diagnosis, the majority of patients have clinical Stage 1b or more locally advanced 
disease, as defined by IMIG. These patients do not benefit from surgery and rapidly 
succumb to their disease. Early detection and early accurate diagnosis can positively 
affect mesothelioma prognosis when patients will be effectively treated. 
 
Conflict of Interest statement: No conflict of interest to be declared.
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Investigational drug approaches Recent progress has reshaped the clinical landscape in the 
treatment of MPM. We have now more effective chemotherapy and from current evidence, 
it is clear that histone deacetylase inhibitors represent a potentially new treatment 
modality in MPM. Among current investigational drugs, mesothelin targeted therapies, 
dendritic cell based immunotherapy and gene therapy hold promise and should be further 
explored. Despite these, actual treatment is still amenable to improvement. Several factors 
have hampered the development of more effective regimens for mesothelioma. MPM is 
uncommon, is heterogeneous, staging is unreliable, response assessement is difficult and 
most drugs do not work. For the staging, the International Mesothelioma Interest Group 
are actually collaborating with the IASLC to include malignant pleural mesothelioma in 
its proposals for the 8th edition of TNM classification. The ability to measure reproducibly 
tumour response to treatment is vital in the development of new drugs and therapeutic 
combinations, particularly for the conducting of phase II studies. Conventional response 
criteria have always been difficult to apply to malignant mesothelioma due to its unique 
pattern of growth. Because the selection of measurement sites in mesothelioma is difficult, 
RECIST criteria could be applied differently by different investigators and that’s why the 
Modified RECIST criteria have been developed. Based on the complex growth pattern 
of MPM, response evaluation in this cancer entity is still challenging. Results on value 
of fluoro-2-deoxy-D-glucose and positron emission tomography imaging ((SUVmean, 
tumor lesion glycolysis (TLG) and tumor volume (PETvol)) in response assessment in 
MPM are promising. Where do we go from here with the systemic therapy for MPM? We 
need better drugs, probably by more accurate preclinical investigation and we have to use 
better the drugs we have: in maintenance therapy, in special populations, in multimodality 
setting. More selectivity regarding the “promising” drug we choose to move from the 
bence to the clinic and fewer “me too” trials are warranted. Better designed trials that 
are adequately powered, multicenter, preferable with randomized phase II design to 
balance for heterogeneity, with appropriate endpoints (PFS, OS, QoL) and with correlative 
studies built in, are mandatory. Methods to assay individual tumor characteristics are 
warranted in order to avoid toxicity in patients who may not respond to treatment and 
losing precious time in a disease associated with a short survival. Drug resistance profiles 
have been reported to various malignant diseases including NSCLC, SCLC, breast, 
ovarian, colon, esophageal and carcinoid tumours. Recently the feasibility of performing 
off-site in vitro drug resistance assays on resected mesothelioma specimens is reported. 
For clinical implementation, a chemoresistance test applicable to pemetrexed should be 
useful. The effectiveness of assay-directed therapy is promising and need to be addressed 
in prospective trials. Multiple biologicals have been studied or are still under investigation, 
however a lot of them seems to fail. It is of great importance that the molecular biologic 
research should focus more on mesothelioma-specific pathways and biomarkers, instead of 
copying mechanisms and treatments that were successful in other tumour types. Looking 
at the list of new VEGFR-inhibitors being tested in MPM, one can question if it is a wise 
use of the limited patient resources to perform so many “me too” trials in this uncommon 
disease? One can question whether trials with so-called targeted agents in an unselected 
population of mesothelioma patients are appropriate. Investigational surgical approaches 
The role of surgery remains controversial and should be further explored. Although the 
multimodality treatment procedure seems feasible, overall treatment time is long and 
psychological distress is considerable. Subgroup analysis of a large Scandinavian phase 2 
combination chemotherapy trial shows a median overall survival of 22 months in patients 
with good performance status, epithelioid subtype, stage I–II and aged 70 years or less, 
equivalent to survival in patients subjected to multimodality treatment. These findings 
stress the importance of a large prospective multicentre, in which operable patients 
with early stage resectable MPM are randomly assigned to a surgical and a non-surgical 
management. The feasibility of this approach has been explored in the UK MARS 1 trial, in 
which the randomisation is between EPP followed by PORT and any palliative treatment, 
including pleurodesis, following an induction treatment with chemotherapy. The results 
of the feasibility part of this trial have recently been released and show no difference in 
survival between both treatment arms. A large retrospective uncontrolled series reports 
that P/D might prolong survival as compared to EPP and that a less invasive procedure 
might hence be preferable in selected patients, provided it is standardised. In a systematic 
review of 1270 patients who had undergone lung-sparing surgery for mesothelioma, overall 
survival was comparable with the outcome reported in historical series including EPP. It 
is expected that a large European multicentre randomised trial will be conducted in the 
coming years, addressing the role of any tumour resection in MPM. Whether the latter will 
include EPP remains to be determined. Investigational radiotherapy approaches The role 
of PORT in MPM is controversial and based on a single uncontrolled retrospective series. 
This additional value of PORT is being addressed in an on-going Swiss study, in which 
eligible patients are randomised after EPP between observation and hemi-thoracic PORT. 
Pleural IMRT allows administering a radical dose of radiotherapy to a MPM with intact 
lung. The role of IMRT with chemotherapy is presently being investigated in patients with 
unresectable disease. Currently a study that looks at whether giving a short intense course 
of chest radiation just prior to surgery will sterilize these tumour cells and thus, avoid or 
reduce contamination of the areas outside the chest cavity is ongoing. The investigators 
hypothesize that short neo-adjuvant (pre-operative) hemi-thoracic IMRT, followed by 
immediate planned extra-pleural pneumonectomy (EPP) (+/- adjuvant chemotherapy) will 
reduce the risk of intra-operative seeding and reduce the incidence of distant metastatic 
disease. Another trial explores the use of tomotherapy to treat mesothelioma more 
aggressively than has been possible before. Tomotherapy’s ability to treat unusual shaped 
tumours, particularly when they are wrapped around sensitive normal tissues (the lung), 
enable higher doses of radiation to be used and this may improve its effectiveness. 
Keywords: mesothelioma, Surgery, chemotherapy, Radiotherapy
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Clinical relevance of BM: Bone metastases are a major source of morbidity for patients 
with solid tumors (Coleman, Clin Cancer Res. 2006). They can decrease the mobility 
and the performance status, and may contribute to arrosion in quality of life for patients 
with lung cancer. Bone metastases are the most common cause of potentially debilitating 
pain (Mercadant, Pain, 1997). Because bone metastases are associated with a loss in bone 
structure integrity, they increase the risk of pathologic fractures, with the consequence of 
surgical or radiological interventions (Saad et al, Cancer, 2007). The incidence of skeletal-
related events (SREs) is becoming a greater concern in the lung cancer setting as patients 
life are extended by advances in antineoplastic treatment strategies (Tsuya et al, Lung 
Cancer, 2007). Each typ of SRE is associated with decreases in function and quality-of 
life. Moreover, pathologic fractures and spinal cord compression can result in prolonged 
convalescence or permanently impaired mobility and can be associated by depression 
and anxiety. Also bone metastases can be the first manifestation of lung cancer in a 
small percentage of patients, up to 40% of patients with advanced lung cancer developed 
bone metastases during the course of their disease (Coleman, Clin Cancer Res. 2006; 
Kagohashi et al, Int J Clin Pract, 2003). 
 
Current management of BM: Currently, treatment of BMs from solid tumors 
including lung cancer, mainly of palliative nature, involves radiation to bone, surgery, 
analgesics and bisphosphonates (Serafini, J Nucl Med, 2001). Multiple generations of 
bisphosphonates have been developed, each with different strength for inhibiting bone 
resorption. Early-generation nitrogen containing bisphosphonates such as pamitronate, 
elentronate, and ibantronate may provide transient palliation of bone pain, but may 
not provide objective long-term clinical benefit (Lipfon, J Support Oncol, 2004). The 
bisphosphonate zoledronic acid, a new-generation high-potential bisphosphonate has 
demonstrated broad clinical utility in managing malignant bone disease from a variety of 
solid tumors and has received international regulary approach (Lipton et al, Clin Cancer 
Res, 2004; Theriault, Expt Rev Anticancer Ther, 2003). Bisphosphonates are, however, 
associated with nephrotoxicity (Rosen et al, Cancer, 2004), which requires monitoring 
and may nessitate initial dose adjustment and withholding of doses. Therefore, combining 
of bisphosphonates with commonly used platinum-based chemotherapy as first-line 
treatment of advanced NSCLC is complicated by the overlapping renal safety profile of the 
two strategies. 
 
A new, innovative option for the management of BM: The receptor activator of nuclear 
factor-kapa B (RANK) and osteoprotegerin (OPG) axis plays a key role in maintaining 
normal bone homeostasis (Fuller et al, J Exp Med, 1998; Lacey et al, Cell, 1998; Lacey et 
al, Am J Pathol, 2000). In preclinical studies, it has been shown that tumor cells induce 
elevated levels of RANK ligant (RANKL) that increase osteolytic activity (Fizazi et al 
Clin Cancer Res, 2003). Denosumab (XGEVA) is a fully humanized monoclonal antibody 
against RANKL (Mc Clung et al, N Engl J Med, 2006). 
It is not cleared by the kidney and is therefore not associated with the same problems 
as bisphosphonates in patients with renal impairment. Denosumab’s safety profile 
estabilished in the large number of patients with advanced solid tumors indicate 
infrequent osteonecrosis of the jaw rates similar to zoledronic acid, clearly fewer acute 
face reactions compared to zoledronic acid, an increase of hypocalcaemia which is not 
associated with symptoms and/or clinical sequelae (Stopeck et al, J Clin Oncol, 2010; 
Fizazi et al, Lancet, 2011; Henry et al, J Clin Oncol, 2011). Denosumab has received 
approval for the prevention of SREs in patients with solid tumors and bone metastases. 
Data from three randomized phase III-denosumab trials conducted in breast cancer, 
prostate cancer, and other solid tumors – including lung cancer - or multiple myeloma 
have been combined in a preplanned integrated analysis(Stopeck et al, J Clin Oncol, 2010; 
Fizazi et al, Lancet, 2011; Henry et al, J Clin Oncol, 2011). Here, patients were equally 
randomized to receive either a monthly subcutaneously denosumab injection (120 mg) 
or intravenous zoledronic acid (4 mg; dose adjusted for renal function). Daily calcium 
and vitamin D supplements were recommended. These analysis has demonstrated that 
denosumab is superior in the prevention of SREs over zoledronic acid by significantly 
prolonging time without SRE, and significantly reducing the SRE’s rate overall. 
Furthermore, this analysis has established denosumab’s safety profile in about 6000 
patients with advanced solid tumors. 
 
The lung cancer subset of the solid tumors/myeloma trial (Henry et al, J Clin Oncol, 2011) 
was separately further investigated by an exploratory analysis assessing overall survival 
for denosumab in comparison to zoledronic acid. A total of 811 patients with lung cancer 
(702 NSCLC; 109 SCLC) were enrolled. The median age of that patients was 61 years, most 
were males and Caucasians. About 90% of patients in both treatment groups received 
prior chemotherapy. More denosumab than zoledronic acid patients had an ECOG status 
of 0 or 1. Overall survival was significantly prolonged with denosumab over zoledronic 
acid in patients with advanced NSCLC and SCLC . Overall survival was not effected 
by prior chemotherapy or differences in ECOG status between the groups. Adverse 
events (AEs) rates were similar between groups. Serious AEs occurred less frequently 
with denosumab than with the zoledronic acid. Osteonecrosis of jaw was balanced, and 
hypocalcaemia appeared more often under denosumab than under zoledronic acid. 
 
Denosumab’s effect on bone metastases in solid tumors including lung cancer 
– conclusion: Denosumab clearly represent a new and innovative option for the 
management of bone metastases. Denosumab offers more benefit than zoledronic acid in 
terms of: a. significantly prolonging time without SRE, regardless of previous SRE history; 
b. consistently favours risk reduction in time to first SRE across tumor types; c. leading to 
significantly fewer SREs across different tumor types; d. significantly prolonging overall 
survival in advanced NSCLC and SCLC. Furthermore, because of denosumab’s favourable 
safety profile and not being nephrotoxic, combining denosumab with standard platinum-
based chemotherapy is not compromised by dose adjustment and dose reduction. 
